Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Amgen investors have been focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...